Werewolf Therapeutics, Inc. reported a net loss of $13.5 million for the first quarter of 2026, a decrease from the $18.1 million loss recorded in the same period of the previous year. The company's operating expenses totaled $13.3 million, down from $18.0 million in the prior year, primarily due to a significant reduction in research and development costs, which fell to $8.2 million from $13.1 million. This reduction reflects the company's strategic decision to curtail spending as it explores various strategic alternatives to enhance stockholder value.
As of March 31, 2026, Werewolf Therapeutics had cash and cash equivalents of $46.5 million, a decrease from $57.1 million at the end of 2025. The company’s total liabilities increased to $45.8 million from $44.6 million, largely due to a rise in accounts payable and accrued expenses. The accumulated deficit also widened to $488.9 million from $475.4 million at the end of the previous fiscal year. The company has not generated any revenue from product sales, as it continues to focus on the development of its therapeutic candidates, including WTX-124 and WTX-330.
In February 2026, Werewolf initiated a restructuring plan that included a workforce reduction of 64% to align resources with its strategic review process. This restructuring is expected to incur approximately $6.4 million in costs, which includes severance payments and other related expenses. The company has engaged Piper Sandler & Co. as its financial advisor to assist in exploring strategic alternatives, which may include asset sales, mergers, or collaborations. The outcome of this review will significantly influence the company's future development plans and funding requirements.
On May 6, 2026, Werewolf entered into an asset purchase agreement with Jazz Pharmaceuticals, selling its 898 Program for $21 million, with an additional $2 million contingent on future agreements. This transaction marks a significant strategic shift for the company, as it also terminated its previous collaboration agreement with Jazz. Additionally, the company repaid all obligations under its K2HV Loan Agreement, totaling approximately $31.4 million, which alleviates some financial pressure but raises questions about future funding sources.
Looking ahead, Werewolf Therapeutics faces substantial uncertainty regarding its ability to continue operations beyond the next twelve months without additional financing. The company plans to update its cash runway guidance soon, but it acknowledges that it will need to secure further capital to fund ongoing operations and development efforts. The strategic review process is expected to inform future funding requirements, but the company has expressed that there is significant doubt about its ability to continue as a going concern.
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics is a biopharmaceutical company developing innovative immunotherapies for cancer and immune-mediated diseases. Using its proprietary PREDATOR platform, it engineers conditionally activated cytokine molecules (INDUKINE) that target the tumor microenvironment, aiming to enhance efficacy while minimizing toxicity. Its pipeline includes cytokine-based therapeutics like IL-2, IL-12, IL-21, IL-18, and IL-10, designed for systemic delivery and tumor-specific activation. The company focuses on immuno-oncology, autoimmune, and inflammatory disease treatments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.